Changes in ocular biometry and anterior chamber parameters after pharmacologic mydriasis and peripheral iridotomy in primary angle closure suspects / Cambios en la biometría ocular y los parámetros de la cámara anterior tras midriasis farmacológica e iridotomía periférica en sospechas de cierre angular primario

Purpose: The aim of this study was to evaluate the effects of pharmacologic mydriasis and Peripheral Iridotomy (PI) on ocular biometry and anterior chamber parameters in primary angle closure suspects. Methods: In this prospective interventional case series, 21 primary angle closure suspects were enrolled. Intraocular pressure, refraction, ocular biometry (Lenstar, LS900), and anterior chamber parameters (Pentacam HR) were measured at four occasions: before PI (before and after mydriasis with phenylephrine) and two weeks after PI (before and after mydriasis). The study was conducted on both eyes and only one eye per patient, in random, was included in the analysis. Results: The mean age of the participants was 60±7 years and 17 (81%) were female. There were no significant differences in intraocular pressure, refraction, keratometry, biometric and anterior chamber parameters between groups, except for anterior chamber volume, which showed increments with PI and mydriasis. The corresponding values for anterior chamber volume were as follows: 88.2±13.7mm3 before PI, undilated; 106.3±18.8 before PI, dilated; 99.0±14.6 after PI, undilated, and 107.4±16.5 after PI, dilated (P<0.001). Conclusions: This study showed no change in the ocular biometric and anterior chamber parameters including iridocorneal angle after PI and/or pharmacologic mydriasis except for increments in anterior chamber volume. This factor has the potential to be used as a numerical proxy for iris position in evaluating and monitoring patients with primary angle closure suspects after PI (AU)

Objetivo: El objetivo de este estudio fue el de evaluar los efectos de la midriasis farmacológica y la iridotomía periférica (IP) en la biometría ocular y los parámetros de la cámara anterior en las sospechas de cierre angular primario. Métodos: En esta serie de casos intervencional prospectiva, se incluyó a 21 sospechas de cierre angular primario. Se realizaron las mediciones siguientes: presión intraocular, refracción, biometría ocular (Lenstar, LS900), y parámetros de la cámara anterior (Pentacam HR) en cuatro ocasiones, antes de la IP (antes y después de la midriasis con fenilefrina) y dos semanas después de la IP (antes y después de la midriasis). El estudio se realizó en ambos ojos, incluyéndose en el análisis un solo ojo por paciente de manera aleatoria. Resultados: La edad media de los participantes fue de 60±7 años, de los cuales 17 eran mujeres (81%). No se hallaron diferencias significativas en cuanto a presión intraocular, refracción, queratometría, parámetros biométricos y de la cámara anterior entre los grupos, exceptuando el volumen de la cámara anterior, que reflejó incrementos con la IP y la midriasis. Los valores correspondientes para el volumen de la cámara anterior fueron los siguientes: 88.2±13,7mm3antes de la IP, sin dilatación; 106.3±18,8 antes de la IP, con dilatación; 99.0±14,6 tras la IP, sin dilatación, y 107.4±16,5 tras la IP, con dilatación (P<0,001). Conclusiones: El presente estudio no reflejó cambios en los parámetros biométricos oculares y de la cámara anterior, incluyendo el ángulo iridocorneal tras la IP y/o midriasis farmacológica, exceptuando los incrementos del volumen de la cámara anterior. Este factor tiene el potencial de ser utilizado como indicador numérico de la posición del iris al evaluar y supervisar a los pacientes con sospechas de cierre angular primario tras IP (AU)

The efficacy of intravitreal interferon alpha-2b for the treatment of experimental endotoxin-induced uveitis.

PURPOSE: To study the efficacy of intravitreal interferon alpha-2b for endotoxin-induced uveitis. MATERIALS AND METHODS: A total of 36 rabbits were randomly allocated to one of the three groups: (1) received interferon plus balanced-salt solution; (2) received lipopolysaccharide (LPS) plus interferon; and (3) received LPS plus balanced-salt solution. Intraocular inflammation was evaluated by slit-lamp biomicroscopy (standardization of uveitis nomenclature grading), binocular indirect ophthalmoscopy (BIO) score, and histopathology. RESULTS: Group 2 showed significantly lower mean (±standard deviation) anterior chamber reaction than Group 3 (3.1 ± 0.9 vs. 3.8 ± 0.4) on day 1 postinjection, lower vitreous cells on days 1 through 7 (day 1: 3.1 ± 0.9 vs. 3.8 ± 0.4; day 3: 2.1 ± 1.6 vs. 3.8 ± 0.4; day 7: 1.9 ± 1.3 vs. 3.6 ± 0.7), and lower BIO score on days 1-7 (day 1: 3.3 ± 1.2 vs. 4.4 ± 0.7; day 3: 3.0 ± 1.4 vs. 4.3 ± 0.9; day 7: 2.4 ± 1.4 vs. 3.7 ± 1.2). The protein content of anterior and vitreous aspirates was lower in Group 2 than 3 (1618.5 ± 411.4 vs. 2567.3 ± 330.8 and 2157.0 ± 283.3 vs. 3204.6 ± 259.5, respectively). CONCLUSION: Intravitreal interferon alpha-2b was effective in controlling endotoxin-induced uveitis.

Changes in ocular biometry and anterior chamber parameters after pharmacologic mydriasis and peripheral iridotomy in primary angle closure suspects.

PURPOSE: The aim of this study was to evaluate the effects of pharmacologic mydriasis and Peripheral Iridotomy (PI) on ocular biometry and anterior chamber parameters in primary angle closure suspects. METHODS: In this prospective interventional case series, 21 primary angle closure suspects were enrolled. Intraocular pressure, refraction, ocular biometry (Lenstar, LS900), and anterior chamber parameters (Pentacam HR) were measured at four occasions: before PI (before and after mydriasis with phenylephrine) and two weeks after PI (before and after mydriasis). The study was conducted on both eyes and only one eye per patient, in random, was included in the analysis. RESULTS: The mean age of the participants was 60±7 years and 17 (81%) were female. There were no significant differences in intraocular pressure, refraction, keratometry, biometric and anterior chamber parameters between groups, except for anterior chamber volume, which showed increments with PI and mydriasis. The corresponding values for anterior chamber volume were as follows: 88.2±13.7mm(3) before PI, undilated; 106.3±18.8 before PI, dilated; 99.0±14.6 after PI, undilated, and 107.4±16.5 after PI, dilated (P<0.001). CONCLUSIONS: This study showed no change in the ocular biometric and anterior chamber parameters including iridocorneal angle after PI and/or pharmacologic mydriasis except for increments in anterior chamber volume. This factor has the potential to be used as a numerical proxy for iris position in evaluating and monitoring patients with primary angle closure suspects after PI.